Literature DB >> 9831594

More large trials needed to decide best duration of treatment with tamoxifen.

D A Cameron.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831594      PMCID: PMC1114352          DOI: 10.1136/bmj.317.7171.1524

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Authors:  B Fisher; J Dignam; J Bryant; A DeCillis; D L Wickerham; N Wolmark; J Costantino; C Redmond; E R Fisher; D M Bowman; L Deschênes; N V Dimitrov; R G Margolese; A Robidoux; H Shibata; J Terz; A H Paterson; M I Feldman; W Farrar; J Evans; H L Lickley
Journal:  J Natl Cancer Inst       Date:  1996-11-06       Impact factor: 13.506

Review 2.  Adjuvant tamoxifen: how long before we know how long?

Authors:  D Rea; C Poole; R Gray
Journal:  BMJ       Date:  1998-05-16

3.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

4.  Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.

Authors:  D C Tormey; R Gray; H C Falkson
Journal:  J Natl Cancer Inst       Date:  1996-12-18       Impact factor: 13.506

5.  Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.

Authors:  H J Stewart; A P Forrest; D Everington; C C McDonald; J A Dewar; R A Hawkins; R J Prescott; W D George
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.